Stem cell pioneer predicts FDA roundtables before year-end

At PepMed 2026 in Washington, stem-cell business leader Chuck Meeker told reporters he believes the Food and Drug Administration will schedule a series of roundtable discussions on regenerative medicine before the year ends. The conference, hosted by the American Academy of Peptide Medicine, focuses on peptide-based therapies, which have recently attracted FDA interest. Meeker highlighted that stem-cell therapies, many of which remain unapproved and operate in a regulatory gray zone, could benefit from the agency’s growing engagement with related technologies.

Industry insiders at the event argued that the FDA’s tentative embrace of peptides may serve as a gateway for stem-cell products to move from the fringe market to broader clinical adoption. The FDA declined to confirm any upcoming meetings. Meeker’s optimism reflects a broader push by the stem-cell sector to secure formal regulatory pathways for its treatments.